Beruflich Dokumente
Kultur Dokumente
Myasthenia Gravis
Address correspondence to
Dr Michael W. Nicolle, London
Health Sciences Centre,
University Hospital,
339 Windermere Rd,
London, ON N6A 5A5, Canada,
mnicolle@uwo.ca.
and Lambert-Eaton
Relationship Disclosure:
Dr Nicolle has given
expert medical testimony
Myasthenic Syndrome
in court cases for the
Canadian Medical
Michael W. Nicolle, MD
Protective Association.
Unlabeled Use of
Products/Investigational ABSTRACT
Use Disclosure:
Dr Nicolle discusses the Purpose of Review: This article discusses the pathogenesis, diagnosis, and management of
unlabeled/investigational autoimmune myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS).
use of azathioprine, Recent Findings: Recognition of new antigenic targets and improved diagnostic methods
mycophenolate, and
rituximab for the treatment
promise to improve the diagnosis of MG, although the clinical phenotypes associated with
of myasthenia gravis and newer antibodies have not yet been defined. Future therapies might specifically target
Lambert-Eaton myasthenic the aberrant immune response. The apparent increase in the prevalence of MG is not
syndrome and the use of
3,4-diaminopyridine for the fully explained. Results of a long-awaited trial of thymectomy support the practice of
treatment of Lambert-Eaton performing a thymectomy under specific conditions.
myasthenic syndrome. Summary: The current treatment options are so effective in most patients with MG or
* 2016 American Academy LEMS that in patients with refractory disease the diagnosis should be reconsidered. The
of Neurology.
management of MG is individualized, and familiarity with mechanisms, adverse effects,
and strategies to manage these commonly used treatments improves outcome. Patient
education is important. LEMS, frequently associated with an underlying small cell lung
cancer, is uncommon, and the mainstay of treatment is symptomatic in most patients.
KEY POINTS
h In more than one-half of cross-link adjacent cell surface AChRs the pathogenesis of MG.9 Although not
the remaining patients resulting in their internalization into the a hereditary disorder in the mendelian
who have acetylcholine muscle cell, or, for some immunoglo- sense, about 3% to 5% of patients with
receptorYnegative bulin subclasses, cause complement MG will have a family member with im-
generalized myasthenia fixation and destruction of the neuro- mune MG, similar to the data from more
gravis, antibodies target muscular junction.2,3 A mixture of anti- than 800 patients in the authors MG
other proteins at the
bodies with each of these mechanisms clinic.10 The prevalence of other autoim-
neuromuscular junction.
The first described
occurs in an individual patient, although mune disorders, especially thyroid, is
and still most prevalent complement-fixing antibodies are likely increased in patients with MG and their
are antibodies against the most common. family members, occurring in 13% to 30%
muscle-specific In more than one-half of the remain- of patients with MG compared with 5% to
tyrosine kinase. ing patients who have AChR-negative 8% in the general population.11,12 This
h The frequent pathologic generalized MG, antibodies target other suggests a genetic influence to autoim-
involvement of the proteins at the neuromuscular junction. mune diseases, of which MG is one of
thymus, especially with The first described and still most prev- the least frequent.
thymic hyperplasia, in alent are antibodies against MuSK. Anti-
some forms of myasthenia Epidemiology
MuSK antibodies are mostly of the
gravis supports the rationale
nonYcomplement-fixing IgG4 subclass Studies show significant heterogeneity
for its removal in select
circumstances, as shown and disrupt neuromuscular transmission in the incidence and prevalence of MG,
by a recent international by interfering with LRP4/MuSK interac- in part because of geographic and ethnic
clinical trial. tion, reducing AChR clustering at the variation. However, recent evidence sug-
h The different ways of muscle endplate.4 More recently, anti- gests that MG is increasingly common,
classifying myasthenia bodies against LRP4, agrin, and cortactin especially in the elderly.13 The incidence
gravis are useful when have been described.5 The significance of of MG ranges between 9 to 30 out of
considering the sensitivity these antibodies is less well delineated. 1 million, and the prevalence ranges
of diagnostic tests as well Pathologic thymic involvement, either from 100 to 140 out of 1 million. How-
as management options. ever, recent studies have shown a pre-
thymic hyperplasia or a thymoma, is
h Congenital myasthenic found in the majority of patients with valence of more than 200 in 1 million.7,14
syndromes are genetic AChR MG.6 Thymic hyperplasia occurs in Women are more likely to have MG than
disorders with a mutation men in the first 5 decades of life whereas
50% to 80% of postpubertal juvenile
in a presynaptic, synaptic,
cases and early-onset adult cases of AChR men are more likely to be diagnosed
or postsynaptic protein
involved in neuromuscular MG.6 Thymic hyperplasia is uncommon with MG after the age of 50.9 Ocular MG
transmission. in MuSK MG and less common in sero- is more common in patients with prepu-
negative and late-onset MG, where the bertal juvenile MG, especially in people of
thymus is often normal, atrophic, or a Asian descent and in men with late-onset
thymoma is found.6,7 The hyperplastic MG. MuSK MG is more frequent in
thymus is a significant source of anti-AChR younger women and possibly in the
antibodies.6,8 A thymoma is found in nonwhite population.
10% to 20% of patients with MG, and MG
occurs in 30% to 50% of thymoma cases. Classification
Although the etiology for MG remains MG can be classified in several ways,
unknown, some subsets of AChR MG are each of which is useful when consider-
associated with specific human leuko- ing diagnostic tests, therapeutic options,
cyte antigen (HLA) determinants, and and prognosis.15,16
subsets of MuSK MG are associated with Age at onset. Congenital myasthenic
other HLA determinants. A recent syndromes are genetic disorders with a
genome-wide association survey in white mutation in a presynaptic, synaptic, or post-
patients with AChR MG showed associa- synaptic protein involved in neuromus-
tion with specific loci that might influence cular transmission. Congenital myasthenic
KEY POINTS
h When antibodies are or IV immunoglobulin (IVIg).21 In the 5% periods is sometimes spontaneously
negative in myasthenia to 10% of patients with immune MG who described. However, patients commonly
gravis, especially when are negative for all known antibodies, the may not remember previous symptoms
patients do not respond diagnosis of MG must always be ques- unless asked specifically. They may have
to treatment as expected, tioned, especially when patients do not been told that previous symptoms were
the diagnosis should respond to treatment. because of a transient ischemic attack or
be reconsidered.
Clinical manifestations and severity. Bells palsy, so a careful history of both
h The way in which a About 50% to 60% of patients present ini- current and previous symptoms is impor-
history of fatigue is elicited
tially with isolated ocular involvement, tant. The patient with unilateral ptosis
is important; direct
most of whom will generalize. Fifteen who had a previous episode of self-
questioning about
worsening weakness at percent to 25% of patients have only limited ptosis on the opposite side
the end of the day may ocular involvement throughout their almost certainly has MG.
falsely suggest a diagnosis course (ocular MG).22,23 Ocular MG is Although characteristic for MG, fati-
of myasthenia gravis. more likely seronegative for AChR anti- gability should be distinguished from
h Most patients (50% to bodies and rarely positive for MuSK. fatigue. The way that a history of fatigue
85%) with myasthenia The role for thymectomy in ocular MG is is elicited is important. An unprompted
gravis present with ocular less certain, and sensitivities of most history of significant fluctuation given by
symptoms with or without diagnostic tests are lower than in gener- the patient is the most specific. Less
generalized weakness. alized MG. Generalized MG includes directed questions (eg, Are there times
About 50% to 60% of
patients with weakness outside of the when your weakness is better or worse?)
patients with myasthenia
gravis present with isolated
ocular muscles, many of whom will also are more useful than asking directly
ocular involvement, have ocular manifestations. The Myas- whether the weakness is worse at the
although many of these thenia Gravis Foundation of America, end of the day. No matter what the cause
(50% to 60%) develop Inc classification is used mostly for for weakness, direct questions will often
generalized weakness research studies but is useful when elicit a history suggesting fatigable weak-
often within the first considering the management options ness and will result in MG being inap-
3 years after onset.
for MG.3 propriately considered in the differential.
Taking the history. When taking the Ocular symptoms. Most patients
history, it is useful to have the patient (50% to 85%) with MG present with
describe what they mean by weakness. A ocular symptoms with or without gener-
history more suggestive of pain, lack of alized weakness. About 50% to 60% of
energy, exhaustion, diffuse nonspecific patients with MG present with isolated
fatigue, or somnolence may not be con- ocular involvement, although many of
sistent with MG. The prevalence of ob- these (50% to 60%) develop generalized
structive sleep apnea is higher in patients weakness often within the first 3 years
with MG; therefore, somnolence secondary after onset. Ocular involvement in-
to a sleep disorder may coexist with MG.24 cludes ptosis, diplopia, or a combina-
The distinguishing clinical feature in tion of these.
MG is fatigable weakness. Fluctuation in Ptosis can be unilateral and, if bilateral,
symptoms is characteristic, although not is usually asymmetric. Persistently sym-
universal, and can occur over short or metric ptosis is more suggestive of a
longer periods of time. Worsening at myopathic etiology, especially chronic
the end of the day is common, although progressive external ophthalmoplegia.
some patients experience worse symp- MG is one of few disorders that can cause
toms first thing in the morning. The complete unilateral (or rarely bilateral)
patient who has no ptosis first thing in ptosis or a history of ptosis alternating
the morning and whose eyes are sides over time.
completely closed at night almost cer- Many patients describe diplopia. Milder
tainly has MG. Fluctuation over longer involvement may produce blurred vision
KEY POINTS
h The diagnosis of asymmetric and even focal within a hand suspected, the examiner should look for
myasthenia gravis is and, very rarely, a footdrop.26 the characteristic and fatigable weakness.
made based on clinical Muscle-specific tyrosine kinase. When To examine a patient for suspected
suspicion, the history and considered as a group, clinical differences fatigable ptosis, the examiner should hold
neurologic examination, exist between patients with AChR and the test object up for at least 60 seconds
and is then supported by MuSK MG. However, significant overlap and watch for obvious worsening. Re-
electrophysiologic and
occurs with the clinical manifestations of peated blinking, which mimics a brief max-
serologic studies.
AChR MG so that predicting MuSK anti- imal voluntary contraction, may transiently
h Myasthenia gravis can body positivity in an individual patient is improve neuromuscular transmission
produce any pattern of
difficult. Patients with MuSK antibodies and mask fatigable ptosis. As the differ-
pupil-sparing extraocular
muscle involvement, are more likely to be female, have early- ential for unilateral ptosis is different
including sixth or third onset MG, and have more severe disease, than for bilateral, looking for enhanced
cranial nerve palsy especially affecting bulbar and respiratory ptosis in the patient with what appears
or internuclear muscles. Rarely is MuSK MG purely ocu- to be unilateral ptosis can be useful.
ophthalmoplegia mimics. lar. Patients with MuSK MG may be more Manual elevation of the obviously ptotic
likely to be oligosymptomatic or mono- eyelid may bring on fatigable ptosis on
symptomatic. Isolated dysphagia, a head the opposite side as the patient is less
drop, or dyspnea without other bulbar reliant on the compensatory use of the
weakness is uncommon in AChR MG frontalis muscle, which may have ob-
but occasionally occurs in MuSK MG scured ptosis on the less affected side.
(Case 11-1). The specificity and sensitivity of the
Cogan eyelid twitch sign (twitching of
Diagnosis the upper eyelid seen when the eyes are
The diagnosis of MG is made based on moved from downgaze back to the
clinical suspicion, the history and neuro- primary position) is widely variable; the
logic examination, and is then supported author does not find this sign useful in
by electrophysiologic and serologic stud- diagnosing MG.
ies. Few diagnostic tests are infallible and The first step when assessing diplo-
some, such as single fiber EMG, are not pia is to establish that it is binocular. If
specific for MG. Undue reliance on diag- monocular (two objects persist when
nostic tests when the clinical picture does one eye is covered), an ophthalmic or
not fit may lead to a false diagnosis of functional origin is likely. MG can pro-
MG.27 Although diagnostic tests in pa- duce any pattern of pupil-sparing extra-
tients with mild, especially ocular, MG ocular muscle involvement, including
may be normal, if no objective support sixth or third cranial nerve palsy or inter-
exists for the diagnosis on at least one nuclear ophthalmoplegia mimics. Down-
test in a patient with significant weakness, gaze is less affected in MG. Although
other diagnoses should be considered. objective limitations in extraocular mus-
Clinical. The biggest delay in diagno- cle movement may be present, usually
sis often results from failure to consider the weakness is subtle and not appreci-
MG in the differential. MG is uncommon, ated by the examiner. It is important for
and most non-neurologists are not famil- the examiner to ask the patient to report
iar with its clinical features. Patients who double vision when assessing the extra-
report significant weakness the previous ocular muscles. Complete symmetric oph-
day but have no objective weakness the thalmoplegia, especially if early in the
next morning are often labeled as func- course, is very uncommon in MG and
tional. Most elderly patients with MG more suggestive of chronic progressive
are first diagnosed as having a stroke or external ophthalmoplegia. Although
transient ischemic attack. Once MG is ptosis can take 60 seconds to fatigue,
diplopia usually appears within 15 to whether the patient can speak in full
30 seconds of sustained gaze. sentences. A single breath count, in which
In any patient who reports dysphagia or the patient counts out loud at approxi-
other significant bulbar weakness, bed- mately 2 Hz from full inspiration until he
side testing of swallowing is best left to a or she needs to take a breath, correlates
speech and language pathologist with roughly with the forced vital capacity in
experience in assessing patients with MG. pulmonary function studies. Counting to
A simple bedside assessment of re- 20 or more suggests that significant re-
spiratory function involves observing spiratory involvement is unlikely. During
KEY POINTS
h The tests used to diagnose the single breath count the examiner be objectively assessed. Ideally, the
myasthenia gravis include should listen for fatigable dysarthria. edrophonium test should be done dou-
repetitive nerve The dysarthria in MG is bulbar and can ble blinded, with syringes of saline or
stimulation and single usually be readily distinguished from edrophonium drawn up by a third per-
fiber EMG. dysarthria in other disorders that might son, and the response to each assessed by
h Routine nerve conduction be mistaken for MG. both patient and examiner blinded to
studies and needle EMG When assessing fatigable limb weak- what is being administered. As there is
are usually normal in ness in patients with possible MG, the often a subjective element to the inter-
patients with myasthenia
author prefers the hands-on method, in pretation of this test, by blinding the
gravis but should almost
which the patient contracts repeatedly edrophonium test, the risk of examiner
always be done first as
myopathic or neurogenic for at least five contractions against resis- and patient bias is reduced. In the ice
conditions may confuse tance. The examiner then looks for grad- pack test, crushed ice in a plastic bag is
the interpretation of ual worsening in power with the last few applied over a ptotic eyelid for 2 to
repetitive nerve stimulation contractions. With profound weakness 5 minutes and then removed.30 PreY
and single fiber EMG. at baseline, demonstrating additional and postYice pack test eyelid positions
h Reduced motor fatigue is difficult. Others prefer to are then compared, ideally by a blinded
amplitudes on motor assess power of a single contraction examiner looking at photographs.
nerve conduction study followed by the patient exercising (eg, Electrophysiologic studies. The tests
is suggestive of clapping hands over the head 20 times) used to diagnose MG include repetitive
Lambert-Eaton
and then reassessing power. The hands-on nerve stimulation and single fiber EMG.1
myasthenic syndrome.
technique allows a better assessment of Routine nerve conduction studies and
h Abnormalities on needle the pattern of fatigue to differentiate from needle EMG are usually normal in pa-
EMG, including fibrillation
nonorganic fatigue, which is often sudden tients with MG but should almost always
potentials, positive
sharp waves, and
with tremulous recruitment. Muscles eas- be done first as myopathic or neurogenic
myopathic motor unit ily assessed for fatigue include deltoids, conditions may confuse the interpreta-
potentials, can be seen in triceps, and hip flexors. It is more tion of repetitive nerve stimulation and
some patients with difficult to convincingly demonstrate fa- single fiber EMG. Reduced motor ampli-
myasthenia gravis, tigue in distal muscles, which are easily tudes on motor nerve conduction study
especially in patients with overcome in normal individuals. Limb is suggestive of LEMS. Both LEMS and
muscle-specific tyrosine
weakness in MG is almost always proximal amyotrophic lateral sclerosis may also
kinase myasthenia gravis.
and symmetric and affects arms more than produce a decrement on repetitive nerve
legs. In the arms, involvement of deltoids stimulation and an abnormal single fiber
and triceps is typical for MG, whereas EMG. Denervation on needle EMG sug-
myopathies more commonly cause weak- gests motor neuron disease. However,
ness of deltoids and biceps. abnormalities on needle EMG, including
The quantitative myasthenia gravis test fibrillation potentials, positive sharp waves,
and similar scales incorporate measures and myopathic motor unit potentials,
of ocular, bulbar, respiratory, and ex- can be seen in some patients with MG, es-
tremity strength and fatigue.28 Although pecially in patients with MuSK MG.31
used mostly for research trials, the When a diagnosis of MG is serologi-
quantitative myasthenia gravis test score cally proven, electrophysiologic testing
can be used in clinical practice to follow may not be necessary. However, repet-
patients during treatment. itive nerve stimulation is a useful exten-
The ice pack and edrophonium tests sion of the clinical examination when
have similar sensitivities and specific- determining whether the patients symp-
ities.29 Increasing difficulties in obtain- toms are secondary to MG. However,
ing edrophonium means that this test is many muscles, including extraocular and
rarely done. If performed, there must be a most bulbar and leg muscles, are not
clear end point (usually ptosis) that can accessible for repetitive nerve stimulation
FIGURE 11-1 Single fiber EMG showing A, jitter at more than 200 sec; B, jitter at
more than 700 sec and blocking in more than 60% of muscle fiber
action potentials.
KEY POINTS
h The acetylcholine receptor muscles remote from the injection site or MuSK as well as in other disorders,
antibody titer does not so that an abnormal single fiber EMG including amyotrophic lateral sclerosis.42
correlate well with clinical must always be considered with caution It is uncertain whether a specific clinical
severity in an individual after botulinum toxin.35 phenotype is associated, although early
patient, and it is not useful Serologic studies. Although the sen- evidence suggests that LRP4 is found
to follow antibody sitivity of antibody testing is low in some in ocular as well as in mild to moderate
levels serially.
situations (eg, ocular MG), the specific- generalized MG.42
h Novel antigenic targets ity for the diagnosis of MG is very high Even more recently, antibodies against
have been recently
(more than 99% for AChR antibodies).29,36 agrin or cortactin have been reported in MG.
discovered in patients
In the right clinical context, positive anti- Their pathogenic relevance and associated
with myasthenia gravis.
bodies confirm a diagnosis of MG. Posi- clinical phenotype are uncertain21,45,46
h Positive serologic tests in tive AChR antibodies also correlate with Although often used as a diagnostic
myasthenia gravis both
thymic pathology (either thymic hyper- criterion in published studies of MG,
confirm the diagnosis as
well as help guide plasia or a thymoma), whereas MuSK especially ocular MG, a frequent diag-
management options. antibodies, for the most part, do not.15 nostic pitfall is overreliance on response
h Response to treatment, Thus, knowledge of the serostatus guides to treatment. This false-positive response
especially to pyridostigmine investigations and treatment options. is especially common with pyridostigmine
and IV immunoglobulin, AChR antibodies are present in approx- and IVIg (Case 11-2) for several reasons,
may be useful as a imately 50% of patients with ocular MG including a placebo effect, especially in
diagnostic test but only and 85% of patients with generalized patients with pseudo-MG. Many patients
when supported by MG.29 A small percentage of initially with nonspecific fatigue pursue an Inter-
clinical features and, AChR-negative patients may become se- net diagnosis leading to a self-diagnosis
preferably, other objective
ropositive, usually in the first year.37 More of MG. Improvement with treatment is
diagnostic tests.
recent improvements in the assay using taken to confirm the diagnosis of MG,
clustered AChRs in cell-based assays re- even when all other diagnostic tests are
veal positive AChR antibodies in 50% of negative. Some patients come to the
previously seronegative patients. This neurologist well versed in the symptoms
assay is more demanding technically and of MG, and asking about specific details
is not yet widely available.7,38 The AChR of each symptom is essential to help
antibody titer does not correlate well with patients differentiate what is occurring
clinical severity in an individual patient, from what they have read about. Subjec-
and it is not useful to follow antibody tive response to treatment should only be
levels serially.39 Negative AChR antibodies used to diagnose MG if it is unequivocally
make a thymoma extremely unlikely.15,40 and objectively verified. IVIg may pro-
MuSK antibodies are found in approx- duce a nonspecific sense of well-being,
imately 40% (range of 0% to 70%) of the independent of its specific benefits in
15% AChR-negative generalized MG MG. Finally, some disorders in the differ-
group but are rarely positive in patients ential for immune MG may also respond
with ocular MG.21,37,41 The range of MuSK to symptomatic treatments including
sensitivities may reflect geographic and congenital myasthenic syndromes, mito-
ethnic variation as MuSK is more com- chondrial myopathies, and LEMS. If in
mon in the nonwhite population.14,21,42,43 doubt, with the patients consent, a
More recently, LRP4 antibodies have blinded trial of active therapy versus
been found in a small number (approxi- placebo can sometimes establish whether
mately 18%) of patients who are negative the benefit is biological (Case 11-2).
for AChR and MuSK,42 although other Ancillary investigations. A CT chest
studies suggest a lower frequency.44 Their is indicated in patients with AChR MG,
role in MG is less certain as they may oc- although many neurologists will arrange
cur in patients who are positive for AChR one in all MG patients. Its main indication
KEY POINT
h Vitamin B12 deficiency enlarged, and a normal or small thymus Differential Diagnosis
or thyroid disease may on CT may still be hyperplastic.47 Thymic With a characteristic history of fluctuat-
produce nonspecific hyperplasia can occur in other autoim- ing weakness and an appropriate pattern
symptoms that can mune conditions including systemic lupus of weakness, a clinical diagnosis of MG
complicate the erythematosus and autoimmune thyroid often seems secure. However, many
management of disease. If considering thyroid eye disease, patients report worsening of their weak-
myasthenia gravis if
looking for enlarged extraocular muscles ness at the end of the day even when the
not recognized.
on a CT or MRI of the orbits is useful. ultimate diagnosis is not MG, and some
The prevalence of other autoimmune conditions can mimic the symptoms and
diseases is increased in MG. Without sug- signs of MG.
gestive clinical features, the yield of Ocular. Ocular MG is often more dif-
screening for most autoimmune diseases ficult to diagnose than generalized MG,
is low. However, the routine determina- and the sensitivity of diagnostic tests is
tion of vitamin B12 and thyroid levels is lower. Many conditions can mimic ocu-
useful as vitamin B12 deficiency or thy- lar MG (Table 11-1).27 Ophthalmologic
roid disease may produce nonspecific conditions, including levator dehiscence or
symptoms that can complicate the man- a decompensated phoria, are common
agement of MG if not recognized. eventual diagnoses when ocular MG is
Generalized Myasthenia
Anatomic Ocular Myasthenia Gravis Gravis
Ophthalmic Thyroid eye disease, levator Not applicable
dehiscence, phoria, tropia
Central nervous Blepharospasm, brainstem Amyotrophic lateral sclerosis,
system lesion (eg, multiple sclerosis, Parkinson disease/parkinsonism
ischemia, mass lesion,
Wernicke encephalopathy)
Peripheral
nervous system
Nerve Microvascular/diabetic cranial Amyotrophic lateral sclerosis,
neuropathies, Horner syndrome, Guillain-Barre syndrome,
Miller Fisher syndrome, focal neuropathies affecting
isolated/combined III, IV, and craniobulbar function
VI cranial neuropathies
Neuromuscular Lambert-Eaton myasthenic Lambert-Eaton myasthenic
junction syndrome,a botulism, congenital syndrome, botulism, congenital
myasthenic syndrome myasthenic syndrome,
organophosphate toxicity
Muscle Chronic progressive Chronic progressive external
external ophthalmoplegia, ophthalmoplegia, other
oculopharyngeal muscular mitochondrial myopathies,
dystrophy, myotonic dystrophy oculopharyngeal muscular
dystrophy, myotonic dystrophy
Other Idiopathic, convergence spasm Systemic disease, thyroid disease,
idiopathic , chronic fatigue,
functional/conversion disorder
a
Ocular manifestations are rare at onset of Lambert-Eaton myasthenic syndrome.
KEY POINTS
h A complete lack of in print form in addition to a verbal Rarely, patients need lower initial doses
response to treatment is discussion saves time and reinforces the or a slower rate of escalation. Having
unusual in patients with message. Sending a list of the medica- already discussed the next options with
myasthenia gravis and tions that should be avoided in patients the patient at the time of medication
should prompt physicians with MG to the primary care physician initiation, the author has the patient call
to reconsider the diagnosis is useful, although this is not infre- to provide an update on his or her re-
of myasthenia gravis in
quently ignored. Finally, a discussion sponse 2 weeks after starting the medica-
patients who are
seronegative or reconsider
of which symptoms might be secondary tion. Even when a complete response
whether myasthenia to MG (weakness) and which almost never occurs, occasionally symptoms will break
gravis is the cause of the occur (eg, pain, memory loss, sensory through over the next several months. If a
symptoms in patients who symptoms, systemic disorders) maximizes partial response occurs, further increases
are seropositive. efficiency of the neurologists time. of 30 mg to 60 mg at each dose can be
h Many treatments of Management of ocular myasthenia made at intervals of 1 to 2 weeks up to
myasthenia gravis take gravis. Although not life-threatening, ocu- a maximum of 480 mg/d, depending on
time to reach maximal lar MG can be disabling. The first decision tolerance. Higher doses are unlikely to
efficacy, and another is whether symptoms require treatment. produce additional benefit. Diarrhea,
cause for nonresponse to
When symptoms are mild and infrequent, one of the more common side effects,
treatment is unreasonable
expectations about how
it may be best to defer treatment until is often self-limited, but loperamide helps
long it should take before they become troublesome. A trial of in most cases. If no response occurs, the
improvement begins. pyridostigmine may be warranted, but author moves on to immunosuppression,
the medication is often ineffective or usually adding to pyridostigmine, although
minimally effective, especially for diplo- if it is clear that no response has oc-
pia. The risk to benefit ratio of prednisone curred, the medication could be stopped.
may not be worth accepting. Retrospective Prednisone is very useful in patients
evidence suggests that prednisone may with ocular MG, although patience is re-
reduce the risk of generalization.50 How- quired. The evidence in adults that pred-
ever, it may be better to avoid predni- nisone given on alternate days is less
sone when not required, knowing that it likely to cause adverse effects is prac-
is just as likely to be effective if and when tically nonexistent, but starting low doses
MG becomes generalized. (eg, 25 mg every other day) of prednisone
MG is treated symptomatically with will help most patients in about 3 to 4
pyridostigmine, which inhibits acetyl- months.51 Occasionally, patients fluctu-
cholinesterase at the neuromuscular ate and are worse on the off day, and
junction and increases available acetylcho- glycemic control using the alternate-day
line but does not treat the underlying approach is difficult in diabetics, so
immunopathogenesis. Pyridostigmine is sometimes starting or reverting to an
the usual first step in treating ocular MG. equivalent daily dose is required. If at
It has few serious side effects and, if ef- 3 to 4 months the symptoms are not
fective, works quickly. Starting at 30 mg improving (they may not be completely
every 4 hours during the waking day, with gone), doubling the dose to either 25 mg/d
the first tablet taken within an hour of or 50 mg on alternate days helps most of
arising, is a reasonable strategy. Unless the remaining patients. Physicians should
nocturnal symptoms occur, a bedtime be familiar with common side effects of
tablet is wasted. If required, the dose prednisone and discuss these with the
can be increased to 60 mg every 4 hours patient.3 Anticipating worsening in hy-
in 3 to 7 days. The regular 60 mg pyri- pertension and glycemic control and
dostigmine pills have a more consistent enlisting the help of the primary care
bioavailability, and the author rarely physician in managing these is helpful.
uses the sustained-release formulation. Individuals older than age 50 taking more
KEY POINT
h Caution is advised when doses are effective more rapidly. How- effects. In the authors experience, about
starting patients with ever, if high doses (the author considers 1% to 2% of patients, higher in others
myasthenia gravis who doses higher than 30 mg/d as the cutoff experience, will experience a flulike re-
have any bulbar or for concerns about this phenomenon ) action within the first 2 weeks that almost
respiratory weakness on are used initially, about 40% of patients always requires discontinuation. Monitor
high doses of prednisone with MG may worsen initially before they hepatic transaminases (alanine amino-
as patients may
start to improve, and 10% overall worsen transferase [ALT], aspartate amino-
worsen initially.
significantly.54 This usually starts 4 to 5 transferase [AST], and most importantly
days after beginning prednisone and ,-glutamyltransferase [GGT]) and a com-
lasts about 4 to 7 days before improve- plete blood count and differential weekly
ment then occurs. Strategies to avoid for the first 8 weeks and monthly there-
this initial worsening of symptoms in- after. Hepatotoxicity, usually mild and
clude starting at low doses (eg, 10 mg/d) reversible, occurs in 15% and mye-
with increases every 3 to 5 days in 10 mg losuppression in 10% at a median of
steps until the desired dose is reached.55 about 6 weeks after starting.58 Both will
The use of IVIg or plasma exchange when resolve after a dose reduction, although
prednisone is started may also prevent if these adverse effects are rapid or
initial worsening. Prednisone doses of significant, discontinuation may be re-
more than 1 mg/kg/d are rarely required, quired. Neutropenia is the main concern,
and the author usually uses a maximum whereas lymphopenia and macrocytosis
dose of 0.5 mg/kg/d to 0.75 mg/kg/d. are common and benign findings that are
Recent trial evidence suggests that, with seen when monitoring blood work with
patience, most patients respond to rela- long-term azathioprine use. After 6 to
tively low doses of prednisone.56 Predni- 12 months on azathioprine, if no im-
sone takes months (usually 3 to 6 months provement occurs at 150 mg/d, in most
and sometimes longer) before maximum patients not at maximal doses based on
benefit occurs. Higher doses might accel- weight (ie, the patient weighs more than
erate this slightly but definitely increase 50 kg [110 lb]), the dose can be increased
the risk of adverse effects. With bulbar or in 50 mg to 100 mg steps every 3 to 6
respiratory weakness, when a more rapid months to a maximum of 2.5 mg/kg/d to
response is required, immunomodulatory 3.0 mg/kg/d based on actual body weight.
treatments should be used (see the fol- Long-term azathioprine use may increase
lowing section on immunomodulation). the risk of malignancies, particularly der-
In mild generalized MG, if predni- matologic, although the absolute risk of
sone is best avoided, azathioprine can this is low.59 Strategies to reduce this are
be used alone provided the patient can prudent.60 If a risk of or previous
wait the 12 to 18 months (or more) that it history of skin cancers already exists,
may take before optimal benefit is seen.57 using mycophenolate might pose a
Starting prednisone and azathioprine at lower risk.61
the same time takes advantage of the In patients who do not respond to or
earlier benefits from prednisone as tolerate azathioprine, other immuno-
well as the eventual steroid-sparing suppressants can be used. Mycophenolate
effects of azathioprine. Tapering regi- (either mofetil or sodium) is a common
mens are similar to ocular MG (larger next step. Although two trials failed to
reductions at doses of more than 30 mg/d show an additional benefit compared
and smaller below this). Starting aza- to prednisone alone over 36 weeks,
thioprine at 25 mg/d with increases this may reflect the efficacy of predni-
every 2 weeks to 50 mg/d, 100 mg/d, sone in relatively mild MG within the
and 150 mg/d lessens some adverse first 9 months rather than a failure of
KEY POINTS
h Although the specifics of more.70 Rituximab may offer significant Other surgical approaches are used
each indication are still benefits in severe or refractory MG, in some centers. Most consider a cervical
somewhat controversial, especially in those being treated with thymectomy suboptimal because of the
the most accepted long-term IVIg or plasma exchange. risk that thymic tissue will be left behind.
indications for a IgG3 and, to a lesser extent, IgG1 The role for minimally invasive approaches
trans-sternal thymectomy and IgG2 AChR antibodies, which fix (robotic or video-assisted thoracoscopy)
include patients with
complement, can destroy the muscle remains to be proven, although these
generalized early-onset
myasthenia gravis who are
endplate. Therapies targeting comple- approaches are increasingly used in
acetylcholine receptor ment including eculizumab have been many centers. Despite occasional reports
antibody positive and assessed in MG and its experimental of efficacy of thymectomy in MuSK MG,
within 5 years of model and appear promising.70 given the lack of thymic pathology in
disease onset. Thymectomy. Indications for a thy- MuSK MG this remains a controversial
h Many commonly used mectomy in patients with MG include indication.21 Thymectomy in seronega-
medications to treat removal of a thymoma and to increase tive MG, where thymic hyperplasia is
myasthenia gravis, the chance of a sustained drug-free remis- less prominent, is also less proven and a
including pyridostigmine, sion, but these two indications are not chance always exists that a patient who is
prednisone, and
synonymous. Removing a thymoma prob- seronegative does not have MG.
azathioprine, are safe for
use during pregnancy.
ably does not improve the course of MG Pregnancy. For the most part MG is
but is almost always indicated to reduce managed during pregnancy as usual. Plan-
the chance of local growth, invasion, ning any changes in management in ad-
and metastases.71 If removed at an early vance, including before conception when
stage, the long-term survival is good. possible, is important. When MG is well
Once local invasion or metastases occur, controlled, the risks to mother and child
adjuvant therapy with radiation or che- are minimal. Vaginal deliveries are en-
motherapy is usually indicated. couraged, and indications for a cesarean
Given its role in the production of delivery are no different than in a mother
AChR antibodies, removal of a hyper- without MG.75 Although neonatal MG is
plastic thymus has long been considered rare in the authors experience, mothers
a management option for generalized with MG should be managed as a high-
MG. The evidence supporting this is risk pregnancy in a center capable of
mostly retrospective, and evidence-based caring for both neonate and mother.
reviews concluded that thymectomy Most medications used in MG, including
may be a management option in some pyridostigmine, prednisone, and azathio-
patients with MG.72,73 A recently con- prine, appear to be safe in pregnancy.21,76,77
cluded randomized trial supports the Methotrexate and mycophenolate must
role for thymectomy under specific con- be avoided as they are teratogenic. IVIg
ditions in MG.74 Although the specifics and plasma exchange are also relatively
of each indication are still somewhat safe in pregnancy. The severity of the
controversial, the most accepted indica- weakness in MG may improve or worsen,
tions for a trans-sternal thymectomy the latter especially in the puerperium,
include patients with generalized early- during pregnancy.
onset MG who are AChR antibody pos- Other medications and myasthenia
itive and within 5 years of disease onset. gravis. There are many lists of drugs to
The role for thymectomy outside these avoid in MG as they might worsen the
indications is less certain. Improvement weakness in a patient with MG. The
may take 1 to 2 years after thymectomy. evidence supporting inclusion of some
Patients with MG should be medically of these is often weak. Many patients
well controlled and ideally on lower doses with MG, especially the elderly, will be
of prednisone prior to thymectomy. on one or more of these (beta-blockers
KEY POINT
h Patients with feature and that, frequently, patients Clinical. The biggest delay to a diag-
Lambert-Eaton with LEMS have more functional diffi- nosis of LEMS is not suspecting the
myasthenic syndrome culties than predicted by the strength condition. Abnormalities on the neuro-
often present with of individual muscles. logic examination will usually be most
difficulty walking and The clinical features of LEMS usually prominent in the extremities, especially
with leg weakness, with precede the diagnosis of underlying small the legs. Reduced deep tendon reflexes
areflexia and autonomic
cell lung cancer, which is more often at a in a patient where MG is being consid-
involvement comprising
the other two key features.
limited stage or occult when compared ered suggests LEMS instead. Prominent
to small cell lung cancer without LEMS. ocular findings at onset is against a diag-
Weakness almost always begins in the nosis of LEMS.25 Characteristic in LEMS
proximal legs and causes difficulties is the paradox between significant func-
walking.83,85 Arm weakness is also com- tional impairment with walking but only
mon. The onset is often subacute, and mild weakness on examination.
fluctuation is less prominent than in MG. The author has not found clinical
However, ocular and bulbar weakness facilitation in strength, in which the
may be absent or, if present, occur as a second contraction of a muscle group
late manifestation. The presence of ocu- has increased power relative to the first,
lar and perhaps bulbar involvement at to be a reliable sign when elicited by an
onset is strongly against a diagnosis of unbiased examiner. However, in up to
LEMS and suggests MG.25 Thus, LEMS 40% of patients with LEMS, a previously
starts in the legs and ascends while MG absent or significantly reduced deep
often starts with craniobulbar involve- tendon reflex will return to normal after
ment and descends. Respiratory involve- 10 seconds of maximal voluntary con-
ment is uncommon. traction.84 Autonomic involvement is
Deep tendon reflexes are almost al- best established by a careful history.
ways reduced or absent, especially in Many patients will not volunteer symp-
the legs. Involvement of sympathetic toms suggesting autonomic involvement
and perhaps more frequently parasympa- unless asked.
thetic systems occurs eventually in 80% Weakness in a patient with small cell
to 90% of patients with LEMS and can lung cancer is often blamed on cachexia,
produce almost any autonomic manifes- malnutrition, or chemotherapy, and para-
tation. A dry mouth, constipation, and neoplastic LEMS is often not suspected.
erectile dysfunction in men are par- LEMS should be considered when a
ticularly common but loss of sweating, patient with an underlying small cell lung
orthostatic hypotension, and pupillary cancer develops prominent leg weakness
abnormalities are also seen.84 and the deep tendon reflexes are reduced
Sensory loss or cerebellar features are or autonomic involvement occurs.
not features of LEMS but might suggest The prediction of an underlying
an overlapping paraneoplastic disorder small cell lung cancer in patients with
associated with an underlying small cell LEMS may be increased when the pa-
lung cancer. tient has a higher Dutch-English LEMS
Tumor Association Prediction (DELTA-P)
Diagnosis score. This uses clinical features such as
Once suspected, the diagnosis of bulbar weakness (dysarthria, dysphagia,
LEMS can often be made based on chewing weakness, and neck weakness),
characteristic electrophysiologic abnor- autonomic involvement (erectile dys-
malities, which distinguish it from MG. function), weight loss, tobacco use, age
Serologic confirmation of the diagnosis of older than 50 years, and a Karnofsky
is important. Performance Status Scale score of less
KEY POINT
h Whereas pyridostigmine postYmaximal voluntary contraction clinical features of LEMS are often
may not produce studies are as sensitive and better attributed to the effects of cachexia and
significant benefit, tolerated than high-frequency malnutrition. Electrolyte and metabolic
3,4-diaminopyridine is a stimulation.88 Increments of more abnormalities affecting calcium or mag-
very effective than 100% are very suggestive for nesium, as well as hypothyroidism are
symptomatic treatment LEMS but not specific for LEMS
of Lambert-Eaton
also in the differential.
and occur in some cases of
myasthenic syndrome.
botulism and MG. Management
The abnormalities may be subtle The most effective symptomatic treat-
early in the disease course. Although ment in LEMS is 3,4-diaminopyridine
leg weakness is most predominant in (3,4-DAP).92 Through blocking voltage-
LEMS, electrodiagnostic studies of the gated potassium channels, 3,4-DAP
ulnar or median nerves have the highest prolongs nerve terminal depolarization
sensitivities.89 Single fiber EMG abnor- and increases acetylcholine release.79,92,93
malities usually do not distinguish LEMS In small trials, 3,4-DAP has been shown
from MG. to produce clinical and electrophysio-
Serologic studies. VGCC antibodies logic benefit in patients with LEMS.92,94
are more than 90% sensitive in primary Improvement after each dose is usually
autoimmune LEMS and approach 100% in seen within 30 minutes and is maximal
paraneoplastic LEMS.84 VGCC antibodies at 90 minutes. 92 Starting doses are
are not specific and are found in small usually 5 mg to 10 mg three to four
cell lung cancer without LEMS as well as times a day, with gradual increases up
other paraneoplastic disorders.83,90 to 80 mg/d, divided into four to six
Ancillary investigations. Given its doses. Many patients respond to 40 mg/d
association with LEMS, patients should to 60 mg/d. Common adverse effects
be investigated for an underlying small include perioral and acral paresthesia,
cell lung cancer, especially in elderly maximal about an hour after each dose,
smokers with weight loss. If an initial CT nausea, abdominal pain, tachycardia, and
chest is negative, a bronchoscopy or palpitations.92,95 Insomnia is minimized
positron emission tomography (PET) by avoiding the last dose at bedtime.
scan may be indicated in high-risk Doses of more than 100 mg/d may
patients. When initial investigations are increase the risk of seizures, although
negative in a high-risk patient, repeating this is likely a rare adverse effect.92,95
the CT chest every 3 to 6 months for at Seizures are more likely with other pre-
least the first 2 years is suggested, after dispositions, so caution is advised with
which the chance of a small cell lung brain metastases or the use of other
cancer being found is less.91 medications that might lower the thresh-
old for seizures.
Differential Diagnosis In theory, pyridostigmine should be
MG is the disorder most commonly in the synergistic with 3,4-DAP but many pa-
differential for LEMS. A myopathy, espe- tients with LEMS have no benefit from
cially dermatomyositis, might present like pyridostigmine either on its own or in
LEMS in the setting of an underlying small combination with 3,4-DAP.96,97
cell lung cancer. Guillain-Barre syndrome, Given its immunopathogenesis, im-
chronic inflammatory demyelinating poly- munosuppression may also be useful to
radiculoneuropathy (CIDP), and other treat LEMS.97 The choice of immunosup-
motor predominant subacute neuropa- pressant drugs in LEMS is similar to
thies occasionally mimic LEMS. In the MG. However, avoiding immunosup-
context of small cell lung cancer, the pression in paraneoplastic LEMS may
that the diagnosis is incorrect or that the 10. Salvado M, Canela M, Ponseti JM, et al. Study
of the prevalence of familial autoimmune
target symptoms are not directly related myasthenia gravis in a Spanish cohort. J Neurol
to the disease. Symptomatic treatment Sci 2016;360:110Y114. doi:10.1016/j.jns.2015.11.049.
11. Nacu A, Andersen JB, Lisnic V, et al. 24. Nicolle MW, Rask S, Koopman WJ, et al.
Complicating autoimmune diseases in Sleep apnea in patients with myasthenia
myasthenia gravis: a review. Autoimmunity gravis. Neurology 2006;67(1):140Y142.
2015;48(6):362Y368. doi:10.3109/ doi:10.1212/01.wnl.0000223515.15691.26.
08916934.2015.1030614.
25. Wirtz PW, Sotodeh M, Nijnuis M, et al.
12. Gilhus NE, Nacu A, Andersen JB, et al. Difference in distribution of muscle
Myasthenia gravis and risks for comorbidity. weakness between myasthenia gravis
Eur J Neurol 2015;22(1):17Y23. doi:10.1111/ and the Lambert-Eaton myasthenic
ene.12599. syndrome. J Neurol Neurosurg Psychiatry
13. Pakzad Z, Aziz T, Oger J. Increasing incidence 2002;73(6):766Y768. doi:10.1136/
of myasthenia gravis among elderly in jnnp.73.6.766.
British Columbia, Canada. Neurology 2011; 26. Nicolle MW. Wrist and finger drop in
76(17):1526Y1528. doi:10.1212/ myasthenia gravis. J Clin Neuromuscul Dis
WNL.0b013e318217e735. 2006;8(2):65Y69. doi:10.1097/
14. Carr AS, Cardwell CR, McCarron PO, et al. 01.cnd.0000245218.70927.97.
A systematic review of population based 27. Engstrom JW. Myasthenia gravis:
epidemiological studies in Myasthenia diagnostic mimics. Semin Neurol 2004;24(2):
Gravis. BMC Neurol 2010;10:46. doi:10.1186/ 141Y147. doi:10.1055/s-2004-830903.
1471-2377-10-46.
28. Barohn RJ, McIntire D, Herbelin L, et al.
15. Gilhus NE, Verschuuren JJ. Myasthenia gravis: Reliability testing of the quantitative
subgroup classification and therapeutic myasthenia gravis score. Ann NY Acad Sci
strategies. Lancet Neurol 2015;14(10): 1998;841:769Y772. doi:10.1111/
1023Y1036. doi:10.1016/S1474-4422(15)00145-3. j.1749-6632.1998.tb11015.x.
16. Akaishi T, Yamaguchi T, Suzuki Y, et al. 29. Benatar M. A systematic review of
Insights into the classification of myasthenia diagnostic studies in myasthenia gravis.
gravis. PLoS One 2014;9(9):e106757. Neuromuscul Disord 2006;16(7):459Y467.
doi:10.1371/journal.pone.0106757. doi:10.1016/j.nmd.2006.05.006
17. Vincent A, Clover L, Buckley C, et al. Evidence 30. Larner AJ. The place of the ice pack test in
of underdiagnosis of myasthenia gravis in the diagnosis of myasthenia gravis. Int J Clin
older people. J Neurol Neurosurg Psychiatry Pract 2004;58(9):887Y888. doi:10.1111/
2003;74(8):1105Y1108. doi:10.1136/ j.1742-1241.2004.00053.x.
jnnp.74.8.1105. 31. Sanders DB, El-Salem K, Massey JM, et al.
Clinical aspects of MuSK antibody positive
18. Mao ZF, Mo XA, Qin C, et al. Incidence
seronegative MG. Neurology
of thymoma in myasthenia gravis: a
2003;60(12):1978Y1980. doi:10.1212/
systematic review. J Clin Neurol 2012;8(3):
01.WNL.0000065882.63904.53.
161Y169. doi:10.3988/jcn.2012.8.3.161.
32. Stalberg EV, Trontelj J, Sanders DB. Single
19. Evoli A, Batocchi AP, Provenzano C, et al. fiber electromyography. Studies in healthy
Thymectomy in the treatment of myasthenia and diseased muscle. 3rd ed. Fiskebackskil,
gravis: report of 247 patients. J Neurol 1988; Sweden: Edshagen Publishing House, 2010.
235(5):272Y276. doi:10.1007/BF00314173.
33. Sanders DB, Stlberg EV. AAEM minimonograph
20. Somnier FE. Clinical implementation of #25: single-fiber electromyography. Muscle
anti-acetylcholine receptor antibodies. J Nerve 1996;19(9):1069Y1083. doi:10.1002/
Neurol Neurosurg Psychiatry 1993;56(5): (SICI)1097-4598(199609)19:9G1069::
496Y504. doi:10.1136/jnnp.56.5.496. AID-MUS193.0.CO;2-Y.
21. Evoli A, Minicuci GM, Vitaliani R, et al. 34. Ukachoke C, Ashby P, Basinski A, et al.
Paraneoplastic diseases associated with Usefulness of single fiber EMG for
thymoma. J Neurol 2007;254(6):756Y762. distinguishing neuromuscular from other
doi:10.1007/s00415-006-0429-z causes of ocular muscle weakness. Can J
Neurol Sci 1994;21(2):125Y128.
22. Nagia L, Lemos J, Abusamra K, et al.
35. Sanders DB, Massey EW, Buckley EG.
Prognosis of ocular myasthenia gravis:
Botulinum toxin for blepharospasm:
retrospective multicenter analysis. Ophthalmology
single-fiber EMG studies. Neurology 1986;
2015;122(7):1517Y1521. doi:10.1016/
36(4):545Y547. doi:10.1212/WNL.36.4.545.
j.ophtha.2015.03.010.
36. Vincent A, Newsom-Davis J. Acetylcholine
23. Grob D, Arsura EL, Brunner NG, et al. The receptor antibody as a diagnostic test for
course of myasthenia gravis and therapies myasthenia gravis: results in 153 validated cases
affecting outcome. Ann N Y Acad Sci and 2967 diagnostic assays. J Neurol Neurosurg
1987;505:472Y499. doi:10.1111/ Psychiatry 1985;48(12):1246Y1252. doi:10.1136/
j.1749-6632.1987.tb51317.x. jnnp.48.12.1246.
61. Chockalingam R, Downing C, Tyring SK. 73. Skeie GO, Apostolski S, Evoli A, et al.
Cutaneous squamous cell carcinomas in Guidelines for treatment of autoimmune
organ transplant recipients. J Clin Med neuromuscular transmission disorders. Eur J
2015;4(6):1229Y1239. doi:10.3390/ Neurol 2010;17(7):893Y902. doi:10.1111/
jcm4061229. j.1468-1331.2010.03019.x.
62. Guptill JT, Sanders DB, Evoli A. Anti-MuSK 74. Wolfe GI, Kaminski HJ, Aban IB, et al.
antibody myasthenia gravis: clinical Randomized trial of thymectomy in
findings and response to treatment in myasthenia gravis. N Engl J Med
two large cohorts. Muscle Nerve 2011;44(1): 2016;375(6):511Y522. doi:10.1056/
36Y40. doi:10.1002/mus.22006. NEJMoa1602489.
63. Evoli A, Bianchi MR, Riso R, et al. Response 75. Ferrero S, Pretta S, Nicoletti A, et al.
to therapy in myasthenia gravis with Myasthenia gravis: management issues during
anti-MuSK antibodies. Ann N Y Acad Sci pregnancy. Eur J Obstet Gynecol Reprod Biol
2008;1132:76Y83. doi:10.1196/annals.1405.012. 2005;121(2):129Y138. doi:10.1016/
j.ejogrb.2005.01.002.
64. Thomas CE, Mayer SA, Gungor Y, et al.
Myasthenic crisis: clinical features, mortality, 76. Norwood F, Dhanjal M, Hill M, et al.
complications, and risk factors for prolonged Myasthenia in pregnancy: best practice
intubation. Neurology 1997;48(5): guidelines from a UK multispecialty
1253Y1260. doi:10.1212/WNL.48.5.1253. working group. J Neurol Neurosurg
Psychiatry 2014;85(5):538Y543. doi:10.1136/
65. Gajdos P, Chevret S, Toyka KV. Intravenous jnnp-2013-305572.
immunoglobulin for myasthenia gravis.
Cochrane Database Syst Rev 2012;12: 77. Sussman J, Farrugia ME, Maddison P, et al.
CD002277. doi:10.1002/14651858. Myasthenia gravis: Association of British
CD002277.pub4. Neurologists management guidelines. Pract
Neurol 2015;15(3):199Y206. doi:10.1136/
66. Bril V, Barnett-Tapia C, Barth D, et al. IVIG practneurol-2015-001126.
and PLEX in the treatment of myasthenia
gravis. Ann N Y Acad Sci 2012;1275:1Y6. 78. Jonkers I, Swerup C, Pirskanen R,
doi:10.1111/j.1749-6632.2012.06767.x. et al. Acute effects of intravenous
injection of beta-adrenoreceptor- and
67. Dhawan PS, Goodman BP, Harper CM, calcium channel at antagonists and
et al. IVIG versus PLEX in the treatment agonists in myasthenia gravis. Muscle
of worsening myasthenia gravis: what Nerve 1996;19(8):959Y965. doi:10.1002/
is the evidence?: a critically appraised (SICI)1097-4598(199608)19:8G959::
topic. Neurologist 2015;19(5):145Y148. AID-MUS493.0.CO;2-7.
doi:10.1097/NRL.0000000000000026.
79. Tarr TB, Wipf P, Meriney SD. Synaptic
68. Dalakas MC. IVIg in the chronic management pathophysiology and treatment of
of myasthenia gravis: is it enough for your
Lambert-Eaton myasthenic syndrome.
money? J Neurol Sci 2014;338(1Y2):1Y2.
Mol Neurobiol 2015;52(1):456Y463.
doi:10.1016/j.jns.2013.12.034.
doi:10.1007/s12035-014-8887-2.
69. Iorio R, Damato V, Alboini PE, et al.
80. Wirtz PW, Nijnuis MG, Sotodeh M, et al.
Efficacy and safety of rituximab for
The epidemiology of myasthenia gravis,
myasthenia gravis: a systematic review and
meta-analysis. J Neurol 2015;262(5):1115Y1119. Lambert-eaton myasthenic syndrome and
doi:10.1007/s00415-014-7532-3. their associated tumours in the northern
part of the province of South Holland. J
70. Dalakas MC. Future perspectives in Neurol 2003;250(6):698Y701. doi:10.1007/
target-specific immunotherapies of s00415-003-1063-7.
myasthenia gravis. Ther Adv Neurol
Disord 2015;8(6):316Y327. doi:10.1177/ 81. ONeill JH, Murray NM, Newsom-Davis J.
1756285615605700. The Lambert-Eaton myasthenic syndrome.
A review of 50 cases. Brain 1988;111(Pt 3):
71. Cosi V, Romani A, Lombardi M, et al. 577Y596. doi:10.1093/brain/111.3.577.
Prognosis of myasthenia gravis: a
retrospective study of 380 patients. 82. Payne M, Bradbury P, Lang B, et al.
J Neurol 1997;244(9):548Y555. Prospective study into the incidence of
doi:10.1007/s004150050142. Lambert Eaton myasthenic syndrome in
small cell lung cancer. J Thorac Oncol
72. Gronseth GS, Barohn RJ. Practice 2010;5(1):34Y38. doi:10.1097/
parameter: thymectomy for autoimmune JTO.0b013e3181c3f4f1.
myasthenia gravis (an evidence-based
review): report of the quality standards 83. Gilhus NE. Lambert-Eaton myasthenic
subcommittee of the American Academy syndrome; pathogenesis, diagnosis, and
of Neurology. Neurology 2000;55(1):7Y15. therapy. Autoimmune Dis 2011;2011:973808.
doi:10.1212/WNL.55.1.7. doi:10.4061/2011/973808.